Trial Profile

A Phase II Study of Combination Nilotinib and Hyper-CVAD in Patients Newly Diagnosed With Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia or Chronic Myeloid Leukemia Blast-Phase Lymphoid Lineage

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 07 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nilotinib (Primary) ; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Folinic acid; Mesna; Methotrexate; Prednisone; Rituximab; Vincristine
Indications Acute biphenotypic leukaemia; Chronic myeloid leukaemia; Precursor B-cell lymphoblastic leukaemia-lymphoma
Focus Therapeutic Use

01 Jan 2015 Status changed from recruiting to active, no longer recruiting as reported by Mayo Clinic record.
05 Mar 2013 Planned End Date changed from 1 Sep 2014 to 1 Sep 2017 as reported by ClinicalTrials.gov record.
24 Dec 2012 New source identified and integrated (Mayo Clinic record, 11-007469).

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com